𧬠Johnson & Johnson Tops Q2 Estimates with Strong Sales Across Segments
Johnson & Johnson reported better-than-expected earnings and revenue for Q2, supported by robust performance in pharmaceuticals and medtech divisions.
š¹ Key Metrics:
- EPS: $2.77 (exp: $2.68)
- Revenue: $23.74B (exp: $22.86B)
- Market Cap / Assets: $373.35B
š What it Means:
The Q2 beat reflects strong execution across J&Jās diversified portfolio. Pharmaceuticals remained the largest contributor, while medical devices also posted solid growth. Despite macroeconomic pressures, the company maintained margin strength, reassuring investors of its stable outlook.
